1. Home
  2. CFND vs PASG Comparison

CFND vs PASG Comparison

Compare CFND & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CFND

C1 Fund Inc.

N/A

Current Price

$4.98

Market Cap

34.2M

Sector

N/A

ML Signal

N/A

PASG

Passage Bio Inc.

HOLD

Current Price

$12.81

Market Cap

28.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFND
PASG
Founded
N/A
2017
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.2M
28.6M
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
CFND
PASG
Price
$4.98
$12.81
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$34.50
AVG Volume (30 Days)
N/A
84.1K
Earning Date
N/A
03-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
N/A
$5.12
52 Week High
N/A
$20.00

Technical Indicators

Market Signals
Indicator
CFND
PASG
Relative Strength Index (RSI) N/A 48.79
Support Level N/A $13.33
Resistance Level N/A $16.12
Average True Range (ATR) 0.00 2.26
MACD 0.00 -0.28
Stochastic Oscillator 0.00 31.51

Price Performance

Historical Comparison
CFND
PASG

About CFND C1 Fund Inc.

C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.

About PASG Passage Bio Inc.

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.

Share on Social Networks: